Analysis of non-melanoma skin cancer across the tofacitinib rheumatoid arthritis clinical programme

Clinical and Experimental Rheumatology

Volumn 35, Issue 4, 2017, Pages 614-622

  Curtis, Jeffrey R ^a   Lee, Eun Bong ^b   Martin, George ^c   Mariette, Xavier ^d   Terry, Ketti K ^e   Chen, Yan ^e   Geier, Jamie ^e   Andrews, John ^e   Kaur, Mandeep ^e   Fan, Haiyun ^e   Nduaka, Chudy I ^e  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b Seoul National University College of Medicine   (South Korea)

^c Dermatology and Laser Center of Maui   (United States)

^d UNIVERSITÉ PARIS SACLAY   (France)

^e PFIZER INC   (United States)

Author keywords

Clinical trial; Non melanoma skin cancer; Rheumatoid arthritis; Tofacitinib

Indexed keywords

METHOTREXATE; TOFACITINIB; ANTIRHEUMATIC AGENT; PIPERIDINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CLINICAL PROTOCOL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ETHNIC DIFFERENCE; FEMALE; GEOGRAPHIC DISTRIBUTION; HEALTH PROGRAM; HUMAN; MAJOR CLINICAL STUDY; MALE; NON MELANOMA SKIN CANCER; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; POPULATION RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VERY ELDERLY; ARTHRITIS, RHEUMATOID; CARCINOMA, BASAL CELL; CARCINOMA, SQUAMOUS CELL; INCIDENCE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SKIN NEOPLASMS;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CARCINOMA, BASAL CELL; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; INCIDENCE; MALE; METHOTREXATE; MIDDLE AGED; PIPERIDINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; PYRROLES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SKIN NEOPLASMS;

EID: 85028655596     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. KHURANA R, WOLF R, BERNEY S et al.: Risk of development of lung cancer is increased in patients with rheumatoid arthritis: a large case control study in US veterans. J Rheumatol 2008; 35: 1704-8
2. HASHIMOTO A, CHIBA N, TSUNO H et al.: Incidence of malignancy and the risk of lymphoma in Japanese patients with rheumatoid arthritis compared to the general population. J Rheumatol 2015; 42: 564-71
3. SIMON TA, THOMPSON A, GANDHI KK, HOCHBERG MC, SUISSA S: Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis. Arthritis Res Ther 2015; 17: 212
4. RAMIRO S, GAUJOUX-VIALA C, NAM JL et al.: Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis 2014; 73: 529-35
5. ASKLING J, FAHRBACH K, NORDSTROM B et al.: Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data. Pharmacoepidemiol Drug Saf 2011; 20: 119-30
6. DREYER L, MELLEMKJAER L, ANDERSEN AR et al.: Incidences of overall and site specific cancers in TNF-a inhibitor treated patients with rheumatoid arthritis and other arthritides-a follow-up study from the DANBIO Registry. Ann Rheum Dis 2013; 72: 79-82
7. le BLAY P, MOUTERDE G, BARNETCHE T, MOREL J, COMBE B: Risk of malignancy including non-melanoma skin cancers with anti-tumor necrosis factor therapy in patients with rheumatoid arthritis: meta-analysis of registries and systematic review of long-term extension studies. Clin Exp Rheumatol 2012; 30: 756-64
8. AMARI W, ZERINGUE AL, McDONALD JR et al.: Risk of non-melanoma skin cancer in a national cohort of veterans with rheumatoid arthritis. Rheumatology (Oxford) 2011; 50: 1431-9
9. MARIETTE X, MATUCCI-CERINIC M, PAVELKA K et al.: Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. Ann Rheum Dis 2011; 70: 1895-904
10. CHAKRAVARTY EF, MICHAUD K, WOLFE F: Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors. J Rheumatol 2005; 32: 2130-5
11. SCOTT DL, IBRAHIM F, FAREWELL V et al.: Tumour necrosis factor inhibitors versus combination intensive therapy with conventional disease modifying anti-rheumatic drugs in established rheumatoid arthritis: TACIT non-inferiority randomised controlled trial. BMJ 2015; 350: h1046
12. HODGE JA, KAWABATA TT, KRISHNASWAMI S et al.: The mechanism of action of tofacitinib-an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. Clin Exp Rheumatol 2016; 34: 318-28
13. FLEISCHMANN R, CUTOLO M, GENOVESE MC et al.: Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs. Arthritis Rheum 2012; 64: 617-29
14. KREMER JM, BLOOM BJ, BREEDVELD FC et al.: The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum 2009; 60: 1895-905
15. KREMER JM, COHEN S, WILKINSON BE et al.: A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone. Arthritis Rheum 2012; 64: 970-81
16. TANAKA Y, SUZUKI M, NAKAMURA H et al.: Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Care Res (Hoboken) 2011; 63: 1150-8
17. TANAKA Y, TAKEUCHI T, YAMANAKA H et al.: Efficacy and safety of tofacitinib as monotherapy in Japanese patients with active rheumatoid arthritis: a 12-week, randomized, phase 2 study. Mod Rheumatol 2015; 25: 514-21
18. BURMESTER GR, BLANCO R, CHARLESSCHOEMAN C et al.: Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet 2013; 381: 451-60
19. FLEISCHMANN R, KREMER J, CUSH J et al.: Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med 2012; 367: 495-507
20. van der HEIJDE D, TANAKA Y, FLEISCHMANN R et al.: Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum 2013; 65: 559-70
21. van VOLLENHOVEN RF, FLEISCHMANN R, COHEN S et al.: Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med 2012; 367: 508-19
22. KREMER J, LI ZG, HALL S et al.: Tofacitinib in combination with nonbiologic diseasemodifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial. Ann Intern Med 2013; 159: 253-61
23. LEE EB, FLEISCHMANN R, HALL S et al.: Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med 2014; 370: 2377-86
24. COHEN SB, KOENIG A, WANG L et al.: Efficacy and safety of tofacitinib in US and non-US rheumatoid arthritis patients: pooled analyses of phase II and III. Clin Exp Rheumatol 2016; 34: 32-6
25. WOLLENHAUPT J, SILVERFIELD J, LEE EB et al.: Tofacitinib, an oral Janus kinase inhibitor, in the treatment of rheumatoid arthritis: safety and clinical and radiographic efficacy in open-label, long-term extension studies over 7 years. Arthritis Rheumatol 2015; 67 (Suppl. 10): Abstract 1645
26. BOYLE DL, SOMA K, HODGE J et al.: The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis. Ann Rheum Dis 2015; 74: 1311-6
27. KREMER J, KIVITZ AJ, SIMON-CAMPOS JA et al.: Evaluation of the effect of tofacitinib on measured glomerular filtration rate in patients with active rheumatoid arthritis. Arthritis Rheum 2014; 66: S196
28. TURNER SM, BEYSEN C, CHARLES-SCHOEMAN C et al.: Increased selective clearance of cholesteryl-ester in patients with rheumatoid arthritis is reversed by treatment with tofacitinib. Arterioscler Thromb Vasc Biol 2013; 33: A124
29. McINNES IB, KIM HY, LEE SH et al.: Openlabel tofacitinib and double-blind atorvastatin in rheumatoid arthritis patients: a randomised study. Ann Rheum Dis 2014; 73: 124-31
30. WINTHROP KL, NEAL J, HRYCAJ P et al.: Evaluation of influenza and pneumococcal vaccine responses in rheumatoid arthritis patients using tofacitinib. Ann Rheum Dis 2013; 72: 107
31. CHARLES-SCHOEMAN C, FLEISCHMANN R, DAVIGNON J et al.: Potential mechanisms leading to the abnormal lipid profile in patients with rheumatoid arthritis versus healthy volunteers and reversal by tofacitinib. Arthritis Rheumatol 2015; 67: 616-25
32. BOYLE DL, WEI N, SINGHAL AK et al.: The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT1 signalling in rheumatoid arthritis. Ann Rheum Dis 2013; 72: 138
33. WOLLENHAUPT J, SILVERFIELD J, LEE EB et al.: Tofacitinib, an oral Janus kinase inhibitor, in the treatment of rheumatoid arthritis: open-label, long-term extension safety and efficacy up to 6 years. Arthritis Rheum 2014; 66: S375
34. WOLLENHAUPT J, SILVERFIELD J, LEE EB et al.: Safety and efficacy of tofacitinib, an oral Janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies. J Rheumatol 2014; 41: 837-52
35. WOLFE F, MICHAUD K: Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum 2007; 56: 2886-95
36. KIM GK, DEL ROSSO JQ, BELLEW S: Skin cancer in asians: part 1: nonmelanoma skin cancer. J Clin Aesthet Dermatol 2009; 2: 39-42
37. LOMAS A, LEONARDI-BEE J, BATH-HEXTALL F: A systematic review of worldwide incidence of nonmelanoma skin cancer. Br J Dermatol 2012; 166: 1069-80
38. BOUKAMP P: Non-melanoma skin cancer: what drives tumor development and progression? Carcinogenesis 2005; 26: 1657-67
39. ROGERS HW, WEINSTOCK MA, FELDMAN SR, COLDIRON BM: Incidence Estimate of Nonmelanoma Skin Cancer (Keratinocyte Carcinomas) in the US Population, 2012. JAMA Dermatol 2015; 151: 1081-6
40. TING PT, KASPER R, ARLETTE JP: Metastatic basal cell carcinoma: report of two cases and literature review. J Cutan Med Surg 2005; 9: 10-5
41. LO JS, SNOW SN, REIZNER GT et al.: Metastatic basal cell carcinoma: report of twelve cases with a review of the literature. J Am Acad Dermatol 1991; 24: 715-9
42. SAMARASINGHE V, MADAN V, LEAR JT: Management of high-risk squamous cell carcinoma of the skin. Expert Rev Anticancer Ther 2011; 11: 763-9
43. KHAN L, BREEN D, ZHANG L et al.: Predictors of recurrence after radiotherapy for nonmelanoma skin cancer. Curr Oncol 2014; 21: e326-e329
44. MARCIL I, STERN RS: Risk of developing a subsequent nonmelanoma skin cancer in patients with a history of nonmelanoma skin cancer: a critical review of the literature and meta-analysis. Arch Dermatol 2000; 136: 1524-30
45. HARRIS RB, GRIFFITH K, MOON TE: Trends in the incidence of nonmelanoma skin cancers in southeastern Arizona, 1985-1996. J Am Acad Dermatol 2001; 45: 528-36
46. PFIZER INC.: Xeljanz prescribing information. Available at http://labeling.pfizer.com/ ShowLabeling.aspx?id=959. Last updated Nov 2012. Accessed 23 Jan 2017